Wall Street analysts expect Karyopharm Therapeutics Inc (NASDAQ:KPTI) to post ($0.97) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Karyopharm Therapeutics’ earnings, with estimates ranging from ($1.15) to ($0.73). Karyopharm Therapeutics reported earnings per share of ($0.60) in the same quarter last year, which indicates a negative year over year growth rate of 61.7%. The company is scheduled to report its next earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that Karyopharm Therapeutics will report full year earnings of ($3.79) per share for the current year, with EPS estimates ranging from ($4.79) to ($3.30). For the next financial year, analysts forecast that the company will post earnings of ($2.71) per share, with EPS estimates ranging from ($4.80) to ($1.58). Zacks’ earnings per share calculations are an average based on a survey of analysts that follow Karyopharm Therapeutics.
Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, May 9th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.25). Karyopharm Therapeutics had a negative net margin of 1,005.85% and a negative return on equity of 119.66%. The firm had revenue of $0.16 million during the quarter, compared to the consensus estimate of $0.75 million.
Several research firms have commented on KPTI. Robert W. Baird reissued an “outperform” rating and issued a $25.00 target price (up from $15.00) on shares of Karyopharm Therapeutics in a report on Friday, July 5th. BidaskClub raised shares of Zumiez from a “sell” rating to a “hold” rating in a report on Saturday, June 22nd. ValuEngine raised shares of Zillow Group from a “hold” rating to a “buy” rating in a report on Thursday, July 11th. HC Wainwright reissued a “buy” rating and issued a $48.00 target price (down from $52.00) on shares of CELYAD SA/ADR in a report on Friday, July 5th. Finally, Wedbush set a $11.00 target price on shares of Sangamo Therapeutics and gave the company a “hold” rating in a report on Monday, July 8th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. Karyopharm Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $17.41.
KPTI stock traded down $0.03 during mid-day trading on Wednesday, hitting $7.88. The stock had a trading volume of 1,116,221 shares, compared to its average volume of 1,841,892. The company has a debt-to-equity ratio of 0.98, a current ratio of 6.19 and a quick ratio of 6.19. Karyopharm Therapeutics has a 52 week low of $3.92 and a 52 week high of $21.71. The stock has a market capitalization of $511.26 million, a price-to-earnings ratio of -2.51 and a beta of 2.43. The stock’s fifty day moving average is $6.56.
Institutional investors have recently made changes to their positions in the stock. Two Sigma Investments LP grew its holdings in shares of Karyopharm Therapeutics by 53.2% during the 4th quarter. Two Sigma Investments LP now owns 611,153 shares of the company’s stock valued at $5,727,000 after purchasing an additional 212,196 shares during the last quarter. FMR LLC grew its holdings in shares of Karyopharm Therapeutics by 51.5% during the 4th quarter. FMR LLC now owns 1,875,140 shares of the company’s stock valued at $17,570,000 after purchasing an additional 637,357 shares during the last quarter. Deutsche Bank AG grew its holdings in shares of Karyopharm Therapeutics by 79.1% during the 4th quarter. Deutsche Bank AG now owns 479,323 shares of the company’s stock valued at $4,489,000 after purchasing an additional 211,764 shares during the last quarter. Premier Asset Management LLC bought a new stake in shares of Karyopharm Therapeutics during the 4th quarter valued at approximately $282,000. Finally, First Midwest Bank Trust Division grew its holdings in shares of Karyopharm Therapeutics by 259.2% during the 1st quarter. First Midwest Bank Trust Division now owns 610,850 shares of the company’s stock valued at $3,567,000 after purchasing an additional 440,769 shares during the last quarter. 84.20% of the stock is currently owned by institutional investors.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.
Further Reading: What is the Bid-Ask Spread?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.